ArticleBlood advances2021
Systemic bevacizumab for refractory bleeding and transfusion-dependent anemia in Heyde syndrome.
Andrew B Song et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
11 papers cite it
this paperpooled itcites it